Stay updated on Ribociclib vs Bevacizumab in First-Line Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Ribociclib vs Bevacizumab in First-Line Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ribociclib vs Bevacizumab in First-Line Metastatic Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the number of patients enrolled and randomized in a clinical trial evaluating the efficacy and safety of first-line treatments for metastatic breast cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:37:38.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes examples of eligibility criteria such as a person's general health condition or prior treatments.
    Difference
    34%
    Check dated 2024-05-22T21:36:57.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:31:42.000Z thumbnail image

Stay in the know with updates to Ribociclib vs Bevacizumab in First-Line Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ribociclib vs Bevacizumab in First-Line Metastatic Breast Cancer Clinical Trial page.